Source study unconfirmed
Story checked
New Drug Protects People With Celiac Disease From Gluten Damage in Clinical Trial : ScienceAlert (opens in a new tab)
sciencealert.com · 2026-10-16
Short answer
Source study unconfirmedNo confirmed study match.
We couldn’t confidently identify the source study behind this story. This leaves its claims unverified — not disproven.
These papers were considered as possible sources, but none could be confirmed as the study behind this story.
Share this check
The story
New Drug Protects People With Celiac Disease From Gluten Damage in Clinical Trial : ScienceAlert
sciencealert.com · 2026-10-16
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
No single source study could be confirmed.
We could not identify a single source study for this article. It may discuss broader research or report findings from a source other than a research paper.
Open claim evidenceSearch result
Source study unconfirmed.
We could not identify a single source study for this article. It may discuss broader research or report findings from a source other than a research paper.
Source layer
The 2 papers the story cites
Source study separated from background citations.
The research anchor for the report.
- Also referencedpresented as earlier work
Antibody-mediated blockade of IL-15 reverses the autoimmune intestinal damage in transgenic mice that overexpress IL-15 in enterocytes
Proceedings of the National Academy of Sciences · 2009
- Also referencedpresented as earlier work
Upcoming Treatments in Celiac Disease: From Luminal Enzymes to Oral Immune Tolerance
United European Gastroenterology Journal · 2026
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 5Not checkedargenx announced positive topline results from a phase 2 clinical trial of FB102 for celiac disease.View evidenceHide evidence
As statedphase 2 clinical trial
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 5Not checkedPatients with celiac disease who received FB102 during a controlled gluten challenge had better preservation of the intestinal lining than those who received placebo.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 5Not checkedThe article says participants treated with FB102 showed fewer signs of gluten-induced injury and a smaller inflammatory immune response in the mucosal lining.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 5Not checkedThe article cautions that the drug was tested under controlled conditions and it is unclear whether it would protect against gluten exposure in real-world settings.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 5Not checkedThe drug FB102 is described as a CD122-targeting therapy that may also be explored for other autoimmune diseases such as vitiligo and alopecia areata.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.
Search results
Candidate papers, not confirmed sources.
Crossref, Europe PMC · 16 candidate papers
Antibody-mediated blockade of IL-15 reverses the autoimmune intestinal damage in transgenic mice that overexpress IL-15 in enterocytes
Proceedings of the National Academy of Sciences · 2009 · Crossref
Upcoming Treatments in Celiac Disease: From Luminal Enzymes to Oral Immune Tolerance
United European Gastroenterology Journal · 2026 · Europe PMC, Crossref
Faculty Opinions recommendation of Mucosal cytokine response after short-term gluten challenge in celiac disease and non-celiac gluten sensitivity.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · 2015 · Crossref
827: TRANSGLUTAMINASE 2 (TG2) INHIBITOR PROTECTS GLUTEN-INDUCED INTESTINAL DAMAGE IN CELIAC DISEASE: TRANSCRIPTOMIC ANALYSIS OF A RANDOMIZED GLUTEN CHALLENGE STUDY
Gastroenterology · 2022 · Crossref
Abstract
2026 · Europe PMC